Hashtag: #BingX
The issuer is solely responsible for the content of this announcement.
Hashtag: #BingX
The issuer is solely responsible for the content of this announcement.
Consumers are Fed-up of Unfinished Renovations Cases
With reference to wide-spread media reports, there have been countless cases of incomplete design and construction projects, where customers have nowhere to appeal and pursue the issue in recent years.
Since design and construction projects usually involve engineering expertise, it is difficult for any ordinary consumer to be equipped with the necessary knowledge to understand the project details, cost and charges. Besides, as the industry has a large number of construction professionals, the manual skills and workmanship of different masters may vary greatly. It is now near impossible for customers to judge how to choose the right interior design company that meets their needs and requirements.
While there is room for improvement in the regulatory and supervision mechanism of the design and decoration industry under the Hong Kong laws and regulations, it makes it difficult to put an end to the incidents of unfinished decoration projects and payment disputes, with which the public from time to time suffers from misrepresentation, fraud, and financial losses during a renovation project. Since the amount in dispute is usually higher than $75,000, which cannot be recovered through the Small Claims Tribunal, and must be referred to a more complicated process through the district court for any claimed amount higher than $3,000,000.
However, this will inevitably create another huge amount of legal fees which an ordinary citizen may not be able to afford. As a result, despite of the decoration company’s irresponsibility and deception, many people would have no choice but to settle the dispute through private negotiations and forgo their own legal rights to pursue the matter, while suffering losses in many cases. This has damaged the reputation of the industry and shed the ethical and professional renovation companies in an undesirable light.
Home101 Establishes the Industry’s First 8-Guarantees on its Matching Platform
The Home101 interior decoration design and construction platform provides smart online matching services and selects the most suitable design decoration and construction service suppliers to fit the customer’s needs.
The platform has initiated a new practice to share customers’ risks and established the industry’s first 8 service guarantees:
1) guarantee the reputation and reliability of franchisees;
2) guarantee compensation in case of project delays;
3) guarantee dedicated person for project supervision;
4) guarantee free handover inspection;
5) guarantee no unfinished work;
6) guarantee sufficient insurance;
7) guarantee consolidated quotation;
8) guarantee safe payment gateway;
Through these protective measures, Home 101 has safeguarded and strengthened the trust between consumers and the interior design and construction companies.
Taking advantage of technology advancement, Home 101 has created an intelligent matching platform, based on fair and transparent data analysis methods to match customers with the most suitable decoration and construction service providers.
Moreover, its business model emphasizes on the strict review and selection of franchise invitation, by a team of industry professionals that has not only gathered famous brand names, but also made both the customers and service providers feel more confident with a complete peace of mind.
Home101 hopes to use the platform as a starting point to gradually enhance the overall industry service quality so as to improve its competitiveness.
Grand Opening Discounts that Customers & Merchants Can Enjoy
To celebrate the grand opening of the Home101 interior decoration design and construction flagship store, we now offer discounted prices on various building materials as a token of appreciation to the support of customers and merchants.
Please call our hotline (+852) 5181 8101 for quotations and orders, or visit our flagship store on the 2nd floor of ihome Center, No. 369 Lockhart Road, Wanchai to purchase on-site.
Hashtag: #Home101
The issuer is solely responsible for the content of this announcement.
Home101 is a one-stop professional decoration design and construction service matching platform, dedicated to providing the most suitable decoration services according to consumers’ needs when building the ideal, comfortable home.
We hope to contribute to improving the service quality and standards of the industry as a whole, and create a customer-oriented service experience. Currently, Home101’s main target audience are local citizens in Hong Kong, where we provide a series of services from building material purchase, decoration design, to project construction, etc.
More than 30 large-scale and experienced decoration companies, as well as more than 20 well-known building materials suppliers have already joined hands with the Home 101 team, where we are dedicated to providing a first-class home decoration experience.
The World Food Program, in cooperation with the provincial government of Phongsaly will continue their school lunch delivery project, aimed to help provide lunch for underprivileged students in the province.

BANGKOK (AP) — Seven Buddhist monks are among nine suspects who are being held in pretrial detention after being arrested for allegedly embezzling assets worth about THB 300 million (USD 8.9 million) from donations received by a temple in Thailand’s northeast, authorities said Thursday.
“Hypertrophic cardiomyopathy is a cardiovascular disease that significantly impacts the quality of life of patients,” said Dr. Xiuhua Feng, Consultant of Cardiology at Kiang Wu Hospital. “We are very pleased to see the approval of mavacamten in Macau, as it will bring hope to local patients living with this chronic and debilitating condition.”
“Macau marks mavacamten’s first approval in LianBio’s licensed territories,” said Yizhe Wang, Ph.D., Chief Executive Officer of LianBio. “This approval is a major milestone for patients in the region and demonstrates LianBio’s commitment to accelerating patient access throughout Asia to innovative new treatments.”
In April 2023, the China National Medical Products Administration (NMPA) accepted with Priority Review the New Drug Application for mavacamten for the treatment of adults with symptomatic oHCM.
In April 2023, LianBio announced positive topline results from the Phase 3 EXPLORER-CN trial investigating mavacamten for the treatment of Chinese patients with symptomatic oHCM. EXPLORER-CN met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in Valsalva left ventricular outflow tract (LVOT) gradient from baseline to week 30 compared to placebo (p<0.001). Additionally, mavacamten demonstrated clinically important improvements for all secondary endpoints, including change from baseline to week 30 in resting LVOT peak gradient, proportion of participants achieving a Valsalva LVOT peak gradient <30 mmHg at week 30, proportion of participants achieving a Valsalva LVOT peak gradient <50 mmHg at week 30, proportion of participants with at least one NYHA class improvement from baseline to week 30, change from baseline to week 30 in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS), and change from baseline to week 30 in left ventricular mass index evaluated by cardiac magnetic resonance imaging. Safety results in the trial were consistent with previous studies of mavacamten in symptomatic oHCM, and no new safety signals were reported.
Hashtag: #LianBio #CAMZYOS
The issuer is solely responsible for the content of this announcement.
CAMZYOS (mavacamten) is the first and only cardiac myosin inhibitor approved by the U.S. FDA indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III oHCM to improve functional capacity and symptoms. It has also received regulatory approvals in Australia, Canada, Brazil, Switzerland and Macau. CAMZYOS is an allosteric and reversible inhibitor selective for cardiac myosin. CAMZYOS modulates the number of myosin heads that can enter “on actin” (power generating) states, thus reducing the probability of force producing (systolic) and residual (diastolic) cross-bridge formation. Excess myosin actin cross bridge formation and dysregulation of the super relaxed state are mechanistic hallmarks of HCM. CAMZYOS shifts the overall myosin population towards an energy sparing, recruitable, super relaxed state. In HCM patients, myosin inhibition with CAMZYOS reduces dynamic left ventricular outflow tract (LVOT) obstruction and improves cardiac filling pressures.
LianBio licensed rights from MyoKardia, now a wholly owned subsidiary of Bristol Myers Squibb, in August 2020 for the development and commercialization of mavacamten in Mainland China, Hong Kong, Macau, Taiwan, Thailand and Singapore. Mavacamten was granted Breakthrough Therapy Designation in China for the treatment of patients with oHCM in February 2022.
Hypertrophic cardiomyopathy (HCM) is a chronic, progressive disease in which excessive contraction of the heart muscle and reduced ability of the left ventricle to fill can lead to the development of debilitating symptoms and cardiac dysfunction. HCM is estimated to affect one in every 500 people globally. The most frequent cause of HCM is mutations in the heart muscle proteins of the sarcomere. In both obstructive and non-obstructive HCM patients, exertion can result in fatigue or shortness of breath, interfering with a patient’s ability to participate in activities of daily living. HCM has also been associated with increased risks of atrial fibrillation, stroke, heart failure and sudden cardiac death.
In China, there are an estimated 1.1 million to 2.8 million patients with HCM.
LianBio is a cross-border biotechnology company on a mission to bring transformative medicines to historically underserved patients in China and other Asian markets. Through partnerships with highly innovative biopharmaceutical companies around the world, LianBio is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, and inflammatory disease. LianBio is establishing an international infrastructure to position the company as a partner of choice with a platform to provide access to China and other Asian markets. For more information, please visit
www.lianbio.com.

On Wednesday, the European Union and ECCIL EuroCham launched a joint program to contribute to gender equality and women empowerment in business and the economy in Laos.

Hashtag: #web3 #fittoearn #play-to-earn #gymetaverse
https://www.linkedin.com/company/gym-aesthetics/
https://www.facebook.com/wellnessmetaverse
https://www.instagram.com/wellnessmetaverse/
The issuer is solely responsible for the content of this announcement.
Gymetaverse is an international Web 3.0 wellness brand that uses Web 3.0 technology to offer everyone a unique fitness experience that rewards users physically and digitally.
Laos is planning to nominate the Baci Ceremony for recognition as a UNESCO Intangible Cultural World Heritage listing.